Perspective Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Perspective Therapeutics Stock Forecast and Price Target
The average price target for Perspective Therapeutics's stock lately set by several renowned analysts is $1.60, which would result in a potential upside of approximately 1.27% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $1.70 and a low estimate of $1.50. If you want to buy CATX stock, it might be a good idea to look at its competitors too.
1.27% Upside
Perspective Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Perspective Therapeutics's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $1.70, which would mean an increase of 100.00%. Over the next seven years, experts predict that Perspective Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$231.55 | Buy/Sell | $284.47 | 19.84% |
| EKTA B Stock Forecast | Elekta AB (publ) | Hold |
18
|
kr75.60 | Buy/Sell | kr83.00 | 3.17% |
| NWBO Stock Forecast | Northwest Biotherapeutics | - |
7
|
$0.49 | Buy/Sell | $8.00 | -100.00% |
| ARAY Stock Forecast | Accuray Inc | Buy |
11
|
$2.19 | Buy/Sell | $8.75 | 265.30% |
| CAPR Stock Forecast | Capricor Therapeutics | Buy |
0
|
$5.41 | Buy/Sell | $13.50 | 232.72% |
Perspective Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last zero years, Perspective Therapeutics's Revenue has fallen from $7.10M to $7.10M – a 0.00% decrease. For next year, analysts predict Revenue of $10.64M, which would mean an increase of 49.86%. By 2030, professionals believe that Perspective Therapeutics's Revenue will decrease by 100.00%, reaching $0.00 – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FBIO Stock Forecast | Fortress Biotech | Buy |
11
|
$1.72 | Buy/Sell | $67.50 | 336.05% |
| PIRS Stock Forecast | Pieris Pharmaceuticals | - |
9
|
$11.72 | Buy/Sell | $7.00 | -100.00% |
| ONTX Stock Forecast | Onconova Therapeutics | Buy |
6
|
$0.68 | Buy/Sell | $11.50 | 929.41% |
.jpg)
Perspective Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last zero years, Perspective Therapeutics's EBIT has fallen from $-15.18M to $-15.18M – a 0.00% decrease. For the next year, analysts predict that EBIT will reach $-36.15M – an increase of 138.14%. Professionals believe that By 2030, Perspective Therapeutics's EBIT will fall to $7.30M – a 148.09% decrease from its current value.
Perspective Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Perspective Therapeutics's EPS has grown by 100.00%, rising from $-0.05 to $0.00. For next year, analysts predict EPS of $-0.13, which would mean an increase of 100.00%. Over the next seven years, experts predict that Perspective Therapeutics's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)